Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GS-0201 |
Synonyms | |
Therapy Description |
Limited information is currently available on GS-0201, a putative PARP inhibitor (Jan 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GS-0201 | GS0201 | PARP Inhibitor (Pan) 31 | Limited information is currently available on GS-0201, a putative PARP inhibitor (Jan 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06167317 | Phase I | GS-0201 + Sacituzumab govitecan-hziy GS-0201 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | 0 |